Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Methods in Molecular Biology (Clifton, N.J.)|August 14, 2012
Improvement of proteolytic stability through in silico engineeringLucy Rutten, Hans de Haard, Theo Verrips
Methods in Molecular Biology (Clifton, N.J.)|August 14, 2012
Expression of VHHs in Saccharomyces cerevisiaeAndrea Gorlani, Hans de Haard, Theo Verrips
Methods in Molecular Biology (Clifton, N.J.)|August 14, 2012
Selection of VHHs under application conditionsEdward Dolk, Theo Verrips, Hans de Haard
Expert Opinion on Therapeutic Patents|January 26, 2018
Therapeutic bispecific antibody formats: a patent applications review (1994-2017)Marie Godar, Hans de Haard, Christophe Blanchetot, et al.
Methods in Molecular Biology (Clifton, N.J.)|September 10, 2018
Display Technologies for Generation of Ig Single Variable DomainsVladimir Bobkov, Bas van der Woning, Hans de Haard
Mabs|October 17, 2017
Personalized medicine with biologics for severe type 2 asthma: current status and future prospectsMarie Godar, Christophe Blanchetot, Hans de Haard, et al.
BMC Biotechnology|September 19, 2007
Lactobacillli expressing llama VHH fragments neutralise Lactococcus phagesAnna Hultberg, Denise M Tremblay, Hans de Haard, et al.
Journal of the Neurological Sciences|September 26, 2021
IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravisGil I Wolfe, E Sally Ward, Hans de Haard, et al.
The Journal of Allergy and Clinical Immunology|June 12, 2018
A bispecific antibody strategy to target multiple type 2 cytokines in asthmaMarie Godar, Kim Deswarte, Karl Vergote, et al.
Retrovirology|February 21, 2015
Neutralisation of HIV-1 cell-cell spread by human and llama antibodiesLaura E McCoy, Elisabetta Groppelli, Christophe Blanchetot, et al.
Pageof 7